Conflicting Data on Spiriva Safety (CME/CE)

BARCELONA (MedPage Today) -- Real-world data indicating excess mortality with the mist version of tiotropium (Spiriva) was countered by further details from the TIOSPIR trial indicating no difference versus the dry powder version, which many here declared the winner in the data duel.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news